Mindmaze Therapeutics Publishes Invitation To The 2026 Annual General Meeting

2026-06-03 01:00:49

(MENAFN- EQS Group)

MindMaze Therapeutics Holding SA / Key word(s): AGMEGM
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
03.06.2026 / 06:45 CET/CEST
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting Geneva, Switzerland – June 3, 2026 – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting (AGM), which will be held on June 25, 2026, at 11:00 a.m. CEST in Geneva, Switzerland. At the AGM, the Board of Directors will propose the re-election of the current Board members and the election of Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors. The agenda also includes the approval of the 2025 Annual Report and financial statements, the election of the members of the Nomination and Compensation Committee, the Independent Proxy and the statutory auditors, as well as votes on the compensation of the Board of Directors and the Executive Committee. Shareholders will also be asked to approve an increase in the Company's conditional share capital. Further details on the proposals and the AGM invitation are available on the Company's website.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX ) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-cleared and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit . Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
...
Media Inquiries:
VSC for MindMaze Therapeutics
... DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Additional features:
File: Press release_MindMaze_AGM 2026 Notice End of Media Release

Language:	English
Company:	MindMaze Therapeutics Holding SA
	Avenue de Secheron 15
	1202 Geneva
	Switzerland
Phone:	+41 22 545 11 16
Fax:	+41 22 545 11 17
E-mail:	...
Internet:
ISIN:	CH1251125998
Listed:	SIX Swiss Exchange
EQS News ID:	2338302


End of News	EQS News Service

2338302 03.06.2026 CET/CEST

MENAFN03062026004691010666ID1111203229

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.